A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

BACKGROUND: Checkpoint inhibitors can induce profound anticancer responses, but programmed cell death protein-1 (PD-1) inhibition monotherapy has shown minimal activity in prostate cancer. A published report showed that men with prostate cancer who were resistant to the second-generation androgen re...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:J Immunother Cancer
Główni autorzy: Graff, Julie N, Beer, Tomasz M, Alumkal, Joshi J, Slottke, Rachel E, Redmond, William L, Thomas, George V, Thompson, Reid F, Wood, Mary A, Koguchi, Yoshinobu, Chen, Yiyi, Latour, Emile, Bergan, Raymond C, Drake, Charles G, Moran, Amy E
Format: Artigo
Język:Inglês
Wydane: BMJ Publishing Group 2020
Hasła przedmiotowe:
Clinical/Translational Cancer Immunotherapy
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7333874/
https://ncbi.nlm.nih.gov/pubmed/32616555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000642
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy